BioCubaFarma is now developing a large business agenda that will boost the operations of two joint ventures overseas, counting with the participation of the Genetic Engineering, Biotechnology, and the Molecular Immunology institutes. The industry expects to attract € 134,9 million to complete domestic projects, improve the manufacturing of finished products and active drug ingredients, as well as the expansion of existing production capabilities. Although the group has received requests from 25 foreign companies from 12 countries; the need for external investment and international partnerships is still a high priority to increase access to state-of-the-art technology and export markets.
Antibodies for therapeutic use in cancer and other chronic non-transmissible diseases.
Recombinant proteins for treating cancer and other chronic non-transmissible diseases
Anti-salmonella vaccines and cholera probiotics.
100,000 liters of plasma per year.